Capex bet on 2.5x capacity; execution risk on margin targets
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
First earnings call post-June 2026 IPO; no prior guidance to compare. H1 delivered strong margins (18.46% EBITDA) but management cites 14% and targets only 15%-16% forward — downside surprise implicit in guidance level.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong demand and pricing power evidenced by 88% utilization and INR6+ Cr advance orders post-IPO. But margin guidance (15%-16% EBITDA forward) contradicts H1 actual of 18.46%, signaling either operational headwinds ahead or conservative guidance. Capex execution over next 2-3 months is make-or-break for delivery on 2.5x capacity promise; no track record yet.
₹33.64 Cr
Revenue · +null% YoY₹3.54 Cr
Reported PAT · +null% YoYFlat
Margins · vs guidance: UnverifiedDid the claims hold up?
118% CAGR revenue growth in recent period
OVERSTATEDH1 FY27 revenue INR33.64 Cr; prior capacity 4MT/day in FY25, now 8MT/day; revenue growth claims unsubstantiated by specific YoY numbers
Advance orders worth INR6+ crores with 30-day execution timeline
METJune 2026 domestic purchase order INR6.46 crores mentioned; confirms order book depth and customer traction
EBITDA margin 15%-16% target post-capex
MISSH1 FY27 actual 18.46% (INR6.21 Cr on INR33.64 Cr revenue); management cites current 14% and targets 14%-15% going forward — lower than reported
88% capacity utilization, nearly at max
METConfirmed in Q&A; supports demand narrative but tight constraint for near-term growth without capex
Earnings quality
What changed since the last call
Post-IPO product pricing +5%
UpgradeSelling price increased INR100→INR105 per product after June 2026 listing; management cites improved inquiries and pricing power post-public offering.
Capacity constraint emergence
Downgrade88% utilization forces capex bet; prior ad-hoc 12-hour shift to 8MT/day now insufficient. Expansion necessary to unlock geographic/export growth.
Margin guidance downside vs. H1 actual
DowngradeH1 FY27 EBITDA 18.46%; forward guidance 14%-15%, suggesting 300-400 bps headwind from capex depreciation, working capital, or operational drag.
Defense tender market entry
NewINR60 lakh license investment for defense procurement; tendered pre-IPO; revenue upcall uncertain and not quantified.
The Q&A
Moderate Q&A pressure on margins (Mukesh Panjwani, Vishvender Singh). Management held margins at 14%-15% target despite questions on capex depreciation and working capital. Some evasion on employee cost drop (attributed to 6-month vs. full-year timing). Direct and candid on capacity constraints and capex timeline.
Capacity & capex timeline — Mukesh Panjwani, WC Securities
Answered88% utilization (almost max); construction to complete in 1-2 months; capex utilization in next 2-3 months. Post-expansion capacity >5,000 metric tons/annum, more than double current.
Margin trajectory post-capex — Mukesh Panjwani, WC Securities
PartialEBITDA margin target 14%-15% (vs. 18.46% H1 actual); will increase after capex with high-margin products and marketing investment. No specific post-capex EBITDA bridge provided.
Capacity data granularity — Vishvender Singh, Prudent Equity
AnsweredFY25 start: 4 MT/day; now 8 MT/day (12-hour shift); post-expansion >2.5x, >5000 MT/annum or 16+ MT/day (24-hour capable).
EBITDA margin sustainability — Vishvender Singh, Prudent Equity
DodgedCurrent EBITDA 14% (after loan repayment benefits); targeting 14%-15% forward. Last 3 years maintained ~15%. June IPO reduced interest burden.
Customer segments & SKU diversification — Milind Shah, individual investor
Answered150+ SKUs; B2B model (dealers, distributors, stockists); main revenue from 9 states; demand from residential, commercial sectors; advance order >INR6 Cr.
Defense tender qualification — Vishvender Singh, Prudent Equity
DodgedDefense tender license; scientist visit required for qualification; if qualified, 100% fund refunded; product line related to engineering services.
IPO fund utilization status — Abhishek Malhotra, Family Office
AnsweredINR10 Cr for capex/machinery; almost complete; machinery purchase modernization ongoing, will complete in 2 months.
Capex rationale vs. 24-hour shift option — Shiv Motto, Liotech Industries
AnsweredOnly 8 labor quarters (8 families); capex adds 12 quarters → 20 families. Modernization required for machinery procurement and local facility approvals. All interconnected.
Margin impact on geographic expansion — Shiv Motto, Liotech Industries
PartialNo margin impact if pricing set per margin setup; product price list standardized per margin. Post-expansion, plan for high-margin products to offset.
Receivable days and working capital — Shiv Motto, Liotech Industries
Answered43-44 days (vs. 45-day MSME benchmark); some payment delay post-Sep; planning per 45-day MSME norm. Recovered INR20 lakh interest on receivables.
Employee cost halving in H1 — Vishvender Singh, Prudent Equity
AnsweredNo employee reduction; 6-month H1 salary (INR81 lakh) vs. full-year salary in prior year (INR1.2 Cr). No staff reduction.
Selling price increase post-IPO — Vishvender Singh, Prudent Equity
AnsweredINR100→INR105 per product (5% increase). Increased inquiries post-listing, improvement in existing customers year-wise.
Export expansion plans — Leo Fernandez, individual investor
PartialPlanning South Africa, Gulf, other European countries. Opportunity ongoing; no specific revenue or timeline quantified.
Guidance
No specific FY27/FY28 revenue target provided
LowManagement alludes to 118% CAGR historically but no forward revenue guide. Only capacity & margin targets given.
EBITDA margin 15%-16% post-capex (target, vs. 14% current)
MediumH1 actual 18.46% contradicts current 14% cite; suggests post-IPO loan repayment boost offset by expansion drag. Post-capex high-margin SKU launch expected to lift margin.
Net margin 10%-11% (target, vs. 10.51% H1 actual)
MediumSustainable at current run-rate; capex depreciation may weigh near-term but management targets offset via product mix.
Capex completion within 1-2 months; utilization within 2-3 months thereafter
MediumINR10 Cr capex (machinery, facility modernization); construction to finish by Dec 2026/Jan 2027. Benefits flagged for FY28.
Post-capex capacity >5000 MT/annum (>2.5x current, >200% increase)
MediumCurrent 8 MT/day (12-hour shift) → 16+ MT/day (24-hour capable) post-expansion. Facility footprint expansion to ~12,632 sq ft.
Risks the call surfaced
Capex execution & stranded capacity
HighCapex bet on >2.5x capacity; if demand stalls post-expansion, ROI erodes and capex depreciation crushes margin. No binding forward orders beyond INR6 Cr.
Margin compression from capex depreciation
MediumH1 EBITDA 18.46%; forward target 14%-15%. 300+ bps downside embedded. If capex depreciation and working capital drain exceed high-margin product offset, target miss likely.
Geographic concentration & expansion execution
MediumOperating in 9 states out of 36; 75% of addressable market untapped. Expansion execution (new distributors, regulatory compliance, working capital) may dilute margins and slow revenue growth.
Customer concentration & B2B channel risk
Medium100% B2B model (dealers, distributors, stockists); no large OEM contracts disclosed. Single large customer loss could materially impact revenue.
Raw material (steel) price volatility
MediumSteel prices remained firm in H1 FY27. 5% price fluctuation pass-through threshold; above 5%, customer bears cost; below 5%, company bears. 95+ bps margin at risk.
Defense tender qualification contingency
LowINR60 lakh license investment for defense tender; scientist visit required for qualification. If fail, 100% refund claimed but refund timing opaque.
Management
Score 7/10. Candid on capacity constraints, capex rationale, and margin compression. Some evasion on employee cost drop (attributed to 6-month vs. full-year timing) and defense tender specifics. Provides specific numbers on capacity, pricing, margins. First earnings call post-IPO; track record short. IPO deployment executed (INR24.25 Cr deployed for machinery, loan repayment, working capital). Capex timeline clear (1-2 months). No misses yet but no large-scale execution history.
1 · Dec 2026 (est.)
Capex modernization completion; new machinery commissioning
2 · Jan-Mar 2027
Post-capex utilization; 2.5x capacity ramp and high-margin SKU launch
3 · FY28
Margin expansion to 15%-16% EBITDA (management target); export revenue from South Africa, Gulf
Capex execution over next 2-3 months is make-or-break for delivery on 2.5x capacity promise; no track record yet.
The Capex Bet Demands Proof—Margin Compression Is Built In
H1 delivered 18.46% EBITDA margins and 88% capacity utilization, but management guided to 14–15% forward. The gap—over 300 basis points—is the story: capex depreciation and working capital drain, unproven against a mere ₹6 crore advance order book.
18.46%
Actual
14–15%
Management guidance
~300 bps
Capex depreciation + WC drag
Liotech Industries delivered a solid first half. H1 FY27 revenue of ₹33.64 crore generated EBITDA of ₹6.21 crore (18.46% margin) and PAT of ₹3.54 crore (10.51% margin). Demand is real: the company is running at 88% capacity utilization with an advance order book of ₹6+ crore. That's credible. But on the call, management contradicted its own result. When asked about the strong H1 margins, leadership said current EBITDA is 14%—not 18.46%—and guided to 14–15% forward. That gap, over 300 basis points lower than what just shipped, is the tension the quarter must resolve.
What management claimed vs. what holds up
Advance orders ₹6+ crore with 30-day execution
SupportedJune 2026 domestic purchase order ₹6.46 crore confirmed; order depth and customer traction evident
88% capacity utilization, nearly at max
SupportedCurrent 8 MT/day (12-hour shift); prior capacity 4 MT/day in FY25; Q&A confirms figure
EBITDA margin target 15–16% post-capex
ContradictedH1 actual 18.46% (₹6.21 Cr on ₹33.64 Cr); management cites 'current 14%' and targets only 14–15%, contradicting reported result
118% CAGR revenue growth in recent period
OverstatedNo YoY baseline disclosed; prior capacity 4 MT/day (FY25) now 8 MT/day; growth rate unsubstantiated by specific numbers
The margin contradiction is the fulcrum. Management cites loan repayment and IPO proceeds reducing interest burden as drivers of the strong H1 EBITDA. But looking forward, they guide to lower margins—attributing the step-down to capex depreciation and working capital drain. No detailed bridge was provided. Pressed on the gap, management held the line at 14–15% but offered no reconciliation of why H1's 18.46% is unsustainable. Either H1 was an outlier (possible if loan repayment and interest savings were temporary), or the forward guidance is conservative hedging. Neither inspires confidence in the capex payback thesis.
What changed on this call
Three material shifts from pre-IPO to post-IPO:
Pricing power: Post-IPO selling price increased ₹100 → ₹105 per unit (+5%). Management cites improved inquiries and brand traction from June 2026 listing.
Capex commitment: Company deploying ₹10 crore (machinery, facility modernization) on a 2.5x capacity expansion timeline of 1–2 months. ₹24.25 crore of ₹36.02 crore IPO proceeds deployed for machinery, loan repayment, and working capital. Benefits flagged for FY28.
Geographic and product expansion: From 9 states to planned 36-state rollout; 150+ SKUs; defense tender license investment (₹60 lakh); export expansion (South Africa, Gulf) flagged but unquantified.
These are not minor tweaks. The capex bet—more than 3x the quarterly EBITDA—is a leverage point. If it delivers on time and ramps to full utilization, margins recover and geographic expansion becomes viable. If it delays, demand softens post-expansion, or working capital strains mount, Liotech faces stranded capacity and prolonged margin pressure.
The bull-bear ledger
Strong near-term demand: 88% utilization and ₹6+ crore advance orders confirm market pull
Pricing power: 5% post-IPO increase accepted by customer base; TAM upside from residential, commercial, infrastructure sectors
First post-IPO earnings; IPO funds deployed credibly (machinery, debt paydown, working capital)
Capex bet on 2.5x capacity with no binding demand beyond ₹6 crore order book—execution risk material
Margin guidance (14–15% EBITDA forward) is 300+ bps below H1 actual; bridge unexplained; depreciation drag unquantified
Geographic concentration (9 of 36 states); 100% B2B model (dealers, distributors); customer concentration opaque
Defense tender contingency (₹60 lakh) and export revenue unquantified; execution timelines vague
Risks, ranked by how much they should concern a holder
Capex execution delay or cost overrun; stranded capacity post-expansion
High₹10 crore capex (almost 3x H1 EBITDA) with only ₹6+ crore advance orders to absorb new capacity. If ramp is slower than 2–3 months, ROI erodes and capex depreciation crushes margins into FY28.
Margin compression baked into guidance; depreciation and working capital drag unquantified
HighH1 EBITDA 18.46%; forward target 14–15%. No detailed bridge. If capex depreciation alone exceeds 200 bps, working capital becomes a residual. Miss on either could push margins into single digits.
Demand softness post-geographic expansion; customer concentration opaque
Medium9-to-36-state rollout is execution-intensive. 100% B2B model (dealers, distributors) with no large OEM contracts disclosed. Single customer loss or expansion margin bleed (new distributor support, logistics) could flatten growth.
Raw material (steel) price volatility; 5% pass-through threshold leaves company exposed
MediumCompany absorbs steel price changes up to 5%; passes through above. H1 saw firm prices, but upside surprise could compress margins 100+ bps if prices spike.
Defense tender qualification contingent; export revenue timing vague
Low₹60 lakh investment (0.18% of H1 revenue) is immaterial; upside if qualified. South Africa and Gulf exports flagged but unquantified; execution risk deferred to FY28 at earliest.
How the street is reading this
Liotech's stock stands at ₹104, down 57% from its all-time high of ₹244.15 but up 25% off the ₹83.53 low. The drawdown is steep, but context matters. The ATH was set during IPO-day euphoria in June 2026; the sharp decline since reflects the market repricing the capex bet and margin guidance downside against initial post-IPO optimism. The stock is trading above its 20-day (₹94.1) and 50-day (₹96.31) moving averages, suggesting it has found near-term support. RSI at 58.3 is neutral—neither oversold nor overbought—indicating the market is at an equilibrium of indecision.
Ownership is 71.22% promoter-held with zero FII and DII participation. That's typical for a fresh SME IPO but signals the absence of institutional conviction or accumulation. Bulk deal activity in mid-July 2026 shows mixed trading flows (NEO APEX, BONANZA, AIKYAM portfolio trades) but no clear insider accumulation or insider selling pressure near the highs. The quiet institutional absence and the stock's 57% drawdown from ATH suggest the market is waiting for execution proof: capex completion, margin stabilization, and ramp clarity over Q3 FY27 and Q4 FY27.
The debate
The honest read: Liotech is betting its IPO capital on a 2.5x capacity expansion with margin recovery to 14–15% EBITDA post-depreciation. That's not a step-change thesis; it's a steady-state SME playing the mid-tier architectural hardware consolidation wave. The quarter proves demand is real (88% utilization, pricing power, advance orders). But the margin contradiction—18.46% actual vs. 14–15% guided—betrays either operational headwinds management won't quantify or conservative hedging. Neither reads as confidence. Hold the stock through capex completion (expected Dec 2026–Jan 2027) and Q4 FY27 utilization data. If utilization stays above 85% and margins hold above 13% EBITDA post-capex, the thesis survives and re-rating follows. If capacity sits idle or margins compress below 12%, the capex ROI fails.
1 · Capex completion and machinery commissioning
Expected Dec 2026–Jan 2027. Delay or cost overrun is a red flag. Track facility inspection updates and capex deployment via investor communications and Q3 results.
2 · Post-capex utilization and margin recovery in Q4 FY27 results
The 300+ bps margin compression (18.46% → 14–15%) must reverse post-depreciation ramp. If H2 FY27 EBITDA margin falls below 12%, the capex thesis fails and the stock re-rates lower.
3 · Advance order ramp and geographic expansion traction
9-to-36-state rollout execution and export revenue (South Africa, Gulf) must be quantified by Q1 FY28 results. Without binding orders, new capacity sits idle and ROI erodes.
Liotech's H1 delivered strong operational metrics (demand, pricing power, utilization) but left the fundamental question open: Can a small capex-dependent SME execute a 2.5x capacity bet and maintain 14–15% EBITDA margins? The stock is priced for skepticism (down 57% from ATH, zero institutional ownership), which is fair. Accumulate cautiously if capex completes on time and Q4 margins hold; exit if H2 utilization or margins deteriorate. The single number to track: post-capex EBITDA margin in Q4 FY27. Everything else follows from that.